Cargando…

Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model

BACKGROUND: Hepatocellular carcinoma (HCC) is among the most common and lethal human cancers worldwide. Despite remarkable advances in treatment, high mortality in HCC patients remains a big challenge. To develop novel therapeutic strategies for HCC is thus urgently needed to improve patient surviva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teng, Chiao-Fang, Wang, Ting, Wu, Tzu-Hua, Lin, Jia-Hui, Shih, Fu-Ying, Shyu, Woei-Cherng, Jeng, Long-Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288802/ https://www.ncbi.nlm.nih.gov/pubmed/32565925 http://dx.doi.org/10.1177/1758835920922034

Ejemplares similares

Correction notice to “Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model”
por: Teng, Chiao-Fang, et al.
Publicado: (2021)

Increased Expression of Programmed Death Ligand 1 in Hepatocellular Carcinoma of Patients with Hepatitis B Virus Pre-S2 Mutant
por: Teng, Chiao-Fang, et al.
Publicado: (2020)

Role of Insulin-like Growth Factor 1 Receptor Signaling in Stem Cell Stemness and Therapeutic Efficacy
por: Teng, Chiao-Fang, et al.
Publicado: (2018)

Association of Increased Programmed Death Ligand 1 Expression and Regulatory T Cells Infiltration with Higher Hepatocellular Carcinoma Recurrence in Patients with Hepatitis B Virus Pre-S2 Mutant after Curative Surgical Resection
por: Jeng, Long-Bin, et al.
Publicado: (2022)

Combination treatment of pembrolizumab with DC-CIK cell therapy for advanced hepatocellular carcinoma: A case report
por: Huang, Shao M., et al.
Publicado: (2023)

A Next-Generation Sequencing-Based Platform for Quantitative Detection of Hepatitis B Virus Pre-S Mutants in Plasma of Hepatocellular Carcinoma Patients
por: Teng, Chiao-Fang, et al.
Publicado: (2018)

Mini Review: Molecular Interpretation of the IGF/IGF-1R Axis in Cancer Treatment and Stem Cells-Based Therapy in Regenerative Medicine
por: Lin, Syuan-Ling, et al.
Publicado: (2022)

Increased infiltration of regulatory T cells in hepatocellular carcinoma of patients with hepatitis B virus pre-S2 mutant
por: Teng, Chiao-Fang, et al.
Publicado: (2021)

Hepatitis B virus pre-S2 deletion (nucleotide 1 to 54) in plasma predicts recurrence of hepatocellular carcinoma after curative surgical resection
por: Teng, Chiao-Fang, et al.
Publicado: (2020)

Dendritic-Cell-Vaccine-Based Immunotherapy for Hepatocellular Carcinoma: Clinical Trials and Recent Preclinical Studies
por: Jeng, Long-Bin, et al.
Publicado: (2022)

Programmed cell death-1 blockade in combination with stereotactic radiation in an orthotopic mouse model of hepatocellular carcinoma
por: Friedman, David, et al.
Publicado: (2015)

Next-Generation Sequencing-Based Quantitative Detection of Hepatitis B Virus Pre-S Mutants in Plasma Predicts Hepatocellular Carcinoma Recurrence
por: Teng, Chiao-Fang, et al.
Publicado: (2020)

Cbx7 promotes the generation of induced pluripotent stem cells
por: Wang, Chie-Hong, et al.
Publicado: (2023)

Detection of hepatitis B virus pre-S mutants in plasma by a next-generation sequencing-based platform determines their patterns in liver tissues
por: Teng, Chiao-Fang, et al.
Publicado: (2020)

A combination of sorafenib and radiotherapy reduces NF-κB activity and growth of hepatocellular carcinoma in an orthotopic mouse model
por: Chuang, Hui-Yen, et al.
Publicado: (2021)

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1
por: Tai, Yu-Tzu, et al.
Publicado: (2018)

Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1
por: Park, Jang-June, et al.
Publicado: (2021)

Acetylcorynoline Impairs the Maturation of Mouse Bone Marrow-Derived Dendritic Cells via Suppression of IκB Kinase and Mitogen-Activated Protein Kinase Activities
por: Fu, Ru-Huei, et al.
Publicado: (2013)

Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme
por: Jan, Chia-Ing, et al.
Publicado: (2018)

An Orthotopic Implantation Mouse Model of Hepatocellular Carcinoma with Underlying Liver Steatosis
por: Kasashima, Hiroaki, et al.
Publicado: (2020)

Establishment of image‐guided radiotherapy of orthotopic hepatocellular carcinoma mouse model
por: Zhou, Kaixiao, et al.
Publicado: (2023)

Immune checkpoint molecules soluble program death ligand 1 and galectin‐9 are increased in pregnancy
por: Enninga, Elizabeth Ann L., et al.
Publicado: (2017)

Programmed Death Ligand 1-Expressing Classical Dendritic Cells MitigateHelicobacter-Induced Gastritis
por: Go, Du-Min, et al.
Publicado: (2021)

Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy
por: Hage, Carina, et al.
Publicado: (2019)

Ultrasound-Guided Approaches to Improve Orthotopic Mouse Xenograft Models for Hepatocellular Carcinoma
por: About, Ghina Bou, et al.
Publicado: (2019)

Chemopreventive Effect of Phytosomal Curcumin on Hepatitis B Virus-Related Hepatocellular Carcinoma in A Transgenic Mouse Model
por: Teng, Chiao-Fang, et al.
Publicado: (2019)

Regulatory T Cells and Human Myeloid Dendritic Cells Promote Tolerance via Programmed Death Ligand-1
por: Amarnath, Shoba, et al.
Publicado: (2010)

Crohn's disease is facilitated by a disturbance of programmed death‐1 ligand 2 on blood dendritic cells
por: Faleiro, Rebecca, et al.
Publicado: (2019)

Prostate Cancer Metastases Are Strongly Inhibited by Agonistic Epha2 Ligands in an Orthotopic Mouse Model
por: Salem, Ahmed F., et al.
Publicado: (2020)

Concurrent Injection of Unlabeled Antibodies Allows Positron Emission Tomography Imaging of Programmed Cell Death Ligand 1 Expression in an Orthotopic Pancreatic Tumor Model
por: Zhao, Jun, et al.
Publicado: (2020)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition
por: Hakroush, Samy, et al.
Publicado: (2021)

Magnetic Resonance Colonography Enables the Efficacy Assessment of Immune Checkpoint Inhibitors in an Orthotopic Colorectal Cancer Mouse Model()()
por: Chae, Yeon Ji, et al.
Publicado: (2019)

Prognostic Significance of Serum Albumin Level and Albumin-Based Mono- and Combination Biomarkers in Patients with Hepatocellular Carcinoma
por: Jeng, Long-Bin, et al.
Publicado: (2023)

Efficacy and Safety of Programmed Death-1/Programmed Death-Ligand 1 Inhibitor for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis
por: Liao, Pei-Fei, et al.
Publicado: (2023)

Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients
por: Gu, Xiaobin, et al.
Publicado: (2016)

Programmed Death 1 Ligand Expression in the Monocytes of Patients with Hepatocellular Carcinoma Depends on Tumor Progression
por: Asai, Akira, et al.
Publicado: (2020)

Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes
por: Liao, Haotian, et al.
Publicado: (2019)

Programmed cell death‐ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics
por: Mou, Haibo, et al.
Publicado: (2021)

The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
por: He, Shukang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rskatptjfj573s1r5cu2ss35bm